Effect of 200μG/day of vitamin K1 on the variability of anticoagulation control in patients on warfarin: a randomized controlled trial.
- 2013-09
- Thrombosis research 132(3)
- Habeeb Majeed
- Marc Rodger
- Melissa Forgie
- Marc Carrier
- Monica Taljaard
- Dimitrios Scarvelis
- Carol Gonsalves
- Rosendo A Rodriguez
- Philip S Wells
- PubMed: 23953594
- DOI: 10.1016/j.thromres.2013.07.019
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 54
- Population
- 50 out of 54 patients (intervention: n=26; placebo: n=24) with unstable anticoagulation under warfarin
- Methods
- Single-centre randomized, double-blind, placebo-controlled study, 200 μg/day of vitamin K1
- Blinding
- Double-blind
- Duration
- 6 months pre-randomization and 6 months post-randomization
Background
Controversy exists whether low-dose vitamin K supplementation can improve anticoagulation control in patients with unstable anticoagulation under warfarin. In a single- centre randomized, double-blind, placebo-controlled study, we evaluated the effectiveness of 200 μg/day of vitamin K1 in patients with unstable control under warfarin.Methods
Effectiveness of Vitamin K1 supplementation was primarily assessed by the percentage (%) of Time-in-Therapeutic-Range (TTR) and secondarily by the standard deviation (SD) of the patient's INR values; the proportion of out-of-range INRs; and the number of dose changes on warfarin. Their change scores were obtained by subtracting the mean value in the 6 months pre-randomization from the mean value in the 6 months post-randomization. Multivariable linear-regressions identified factors associated with anticoagulation instability.Results
Fifty out of 54 patients were analyzed (intervention: n=26; placebo: n=24). Most indications (87%) for anticoagulation were venous thromboembolism (VTE). The intervention was associated with a greater reduction in the change scores for the SD of INRs between the pre and post-randomization periods compared with placebo. The mean change score was -0.259±0.307 with the intervention and -0.046±0.345 with placebo (p=0.026). There was no effect on the change scores of the (%) TTR (p=0.98), the number of INRs out-of-range (p=0.58) and the number of dose changes (p=0.604). Factors independently associated with increased variability in the SD of INRs were increased alcoholic drinks/week (p=0.017), dosing errors (p=0.0009) and missed INR appointments (p=0.035).Conclusion
Vitamin K1 supplementation reduces the SD of INRs as an indicator of the variability in anticoagulation control in patients treated with warfarin for VTE.Research Insights
There was no effect on the change scores of the (%) TTR (p=0.98)
- Effect
- Neutral
- Effect size
- Small
- Dose
- 200 μg/day
The intervention was associated with a greater reduction in the change scores for the SD of INRs between the pre and post-randomization periods compared with placebo. The mean change score was -0.259±0.307 with the intervention and -0.046±0.345 with placebo (p=0.026).
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 200 μg/day
the number of dose changes (p=0.604)
- Effect
- Neutral
- Effect size
- Small
- Dose
- 200 μg/day
the number of INRs out-of-range (p=0.58)
- Effect
- Neutral
- Effect size
- Small
- Dose
- 200 μg/day